Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Recruiting · NCT07173855 · Interventional (participants receive a specific treatment) · Lead sponsor: Scarborough General Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.
Who can take part
Inclusion criteria
- Age 16 years or older
- Admission orders written to a medical-surgical intensive care unit at a participating site
- Magnesium replacement protocol ordered
Exclusion criteria
- Prior enrollment in or withdrawal from MAGNOLIA trial
- Sustained ventricular tachycardia
- Pre-eclampsia
- Myasthenia gravis
Where it is running
6 locations listed.
- Lakeridge Health Ajax-Pickering - Ajax, Ontario, Canada
- Lakeridge Health Bowmanville - Bowmanville, Ontario, Canada
- Lakeridge Health Oshawa - Oshawa, Ontario, Canada
- Scarborough Centenary Hospital - Toronto, Ontario, Canada
- Scarborough General Hospital - Toronto, Ontario, Canada
- Scarborough Birchmount Hospital - Toronto, Ontario, Canada